Is correct--has been taken over by Relief with all protective rights. But now IMPORTANT to question India... In the JJs contribution of the APRIL stands in the indicated (and best DD whre ever) DD......
.....If even one of these indications can be added to VIP’s clinical indications for use, market cap will increase exponentially above where it is already headed. At risk of pumping, its reasonable to conclude that RLF/NeuroRx may be become the next Moderna, rising like a phoenix from the ashes to become the newest big pharma. GLTA.
CATALYSTS:
1 - Planned "near term uplisting" of RLFTF to NASDAQ (confirmed by CFO in the Biotech Investor Showcase)
2- EAP data on 300+ compassionate use patients
3 -Initiation of the inhalation trial – reported on 2/3/20 with top line results pending 1H2021
4 - I-SPY trial results for inhaled VIP vs remdesavir
5- Inclusion in NIH/TESICO/Active3b Trial (pg 18 of the NeuroRx investor presentation)
6 - BRPA merger completion
7 - Possible stockpiling agreements/OWS/Barda – described as pending phase 3 results with expected purchase of 100k treatments quarterly and 30k treatments up front
8 - Partnership announcements with McKesson, Cardinal and AmerisourceBergen (Reported by CFO orally in the biotech investor presentation)
9 - Mexico, India, Russia feedback/partnerships (reported by CFO in the biotech investor presentation)
MondoBiotech holding AG changes name Therametrics Holding AG “ The company changed its name from mondoBIOTECH holding AG to THERAMetrics holding AG as at 20 June 2013” Notes to the Financial Statements see 1. General Information Page 7
RLF-100, was acquired by RELIEF THERAPEUTICS Holding SA (Swiss Exchange: RLF, OTCBB: RLFTF) from the business combination of RELIEF THERAPEUTICS Holding SA and Therametrics Holding AG in January 2016. THERAMetrics holding AG formerly was known as MondoBIOTECH holding AG.
This is in the top right of the intro to this board when you view via web page
News 
Market Data 
Discover 
